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INTRODUCTION
Prostate  cancer  is  the  most  common  noncutaneous  cancer  among  males.1 It 
accounts for 10% of cancer related deaths in males. According to the American Cancer 
Society,  186330  new  cases  will  be diagnosed  in  2008  and  26000  men  will  die 
from prostate cancer1. Prostate cancer is rarely diagnosed in men younger than 40 years, 
and it is uncommon in men younger than 50 years. Prostate cancer is also found during 
autopsies performed following other causes of death. The rate of this latent or autopsy 
cancer is much greater than that of clinical cancer. In fact, it may be as high as 80% by 
age 80 years. 2
The  diagnosis  and treatment  of  prostate  cancer  continues  to  evolve.  With  the 
development of prostate-specific antigen (PSA) screening and TRUS, prostate cancer is 
being diagnosed earlier in the disease course.
In  the  present  era,  most  patients  present  because  of  abnormalities  in  Prostate 
Specific Antigen (PSA) level or positive digital rectal examination (DRE) findings while 
evaluating for  BPH, rather than metastatic symptoms.  The combination of DRE and 
serum PSA is the most useful first-line test for assessing the presence of prostate cancer 
in an individual.3 However, prostate cancer can be an incidental pathologic finding when 
tissue  is  removed  during  transurethral  resection to  manage  obstructive  prostatic 
symptoms.
The presence of  prostate  disease (prostate  cancer,  BPH, and prostatitis)  is  the 
most important factor affecting serum levels of PSA.4,5,6.  PSA elevations may indicate 
the presence of prostate disease, but not all men with prostate disease have elevated PSA 
levels. Furthermore, PSA elevations are not specific for cancer.
 Findings  from the  DRE  are  crucial.  An  irregular  firm prostate  or  nodule  is 
typical, but many cancers are found in prostates that feel normal. DRE is a test with only 
fair reproducibility even in the hands of experienced examiners that misses a substantial 
proportion of cancers. 7, 8, 9 DRE detects most cancers at an advanced pathologic stage, 
when treatment is less likely to be effective. DRE misses 23% to 45% of the cancers that 
are subsequently found with prostatic biopsies done for serum PSA elevations. 7
A number  of  studies  have  confirmed  the  inability  of  TRUS to  localise  early 
prostate cancer. 10, 11, 12 Rifkin and colleagues10 found that only 60% of prostate cancers 
measuring more than 5 mm on pathologic examination were identified by MRI and that 
ultrasonography identified only 59% of these cancers. Flanigan and associates12 found 
that only 18% of 855 sonographically suspicious quadrants actually contained cancer on 
biopsy,  whereas  65%  of  quadrants  containing  cancer  were  not  sonographically 
suspicious. Any patient with a DRE suspicious for cancer or a PSA elevation should 
undergo prostate biopsy regardless of TRUS findings if an early diagnosis of cancer 
would result in a recommendation for treatment.
The  original  sextant  biopsy  scheme  (one  core  from the  base,  mid,  and  apex 
bilaterally)  significantly  improved cancer detection,  over  digitally  directed biopsy of 
palpable nodules and TRUS guided biopsy of specific hypoechoic lesions. Presti and co-
workers found that adding laterally directed cores from the base and midgland bilaterally 
improved cancer detection from 80% with standard sextant to 96%.13
To  improve  the  detection  rate  with  TRUS  biopsy  various  additional 
modalities have been tried. This includes power Doppler ultrasonography to evaluate the 
neovascularity in patients with prostate cancer. Various studies have shown increased 
cancer detection rates using Doppler-targeted biopsy strategies.14,15,16,17 To evaluate the 
Indian perspective regarding the Doppler directed targeted biopsy strategies, we decided 
to  conduct  a  study  to  evaluate  the  utility  of  power  Doppler  ultrasonography  in  the 
detection of prostate cancer.
AIM
To evaluate the utility of trans rectal ultrasound with power Doppler imaging guided 
biopsy in comparison with grey scale imaging in the detection of prostate cancer, 10 
core biopsy being the reference standard.
REVIEW OF LITERATURE
Prostate cancer is the fourth most common male malignant neoplasm worldwide.18 
Prostate cancer has been the most common visceral malignant neoplasm in U.S. men 
since 1984, now accounting for one third of all such cancers 1. 10% of cancer-related 
death in males is caused by prostate cancer1 The incidence of prostate cancer peaked in 
1992, approximately 5 years after introduction of prostate-specific antigen (PSA) as a 
screening test; it fell precipitously until 1995 and has been rising slowly since then, at a 
slope similar to that observed before the PSA era. 19
According to figures from the American Cancer Society, 186,330 new cases will 
be diagnosed in 2008 and 26,000 men will die from prostate cancer.  Prostate cancer is 
uncommon  in  men  younger  than  50  years. 20 Prostate  cancer  is  also  found  during 
autopsies performed following other causes of death. The rate of this latent or autopsy 
cancer is much greater than that of clinical cancer. In fact, it may be as high as 80% by 
age 80 years. 1
The lifetime risk (from age 0 to 90 years) of death from prostate cancer is 3% and 
the lifetime risk of a diagnosis of prostate cancer is 17% 21
Anatomy and Internal Structure of the Prostate Gland
Overview of Prostate Anatomy 
The adult prostate is a chestnut-shaped organ enveloped in a fibrous capsule. The 
base  of  the  prostate  is  attached  to  the  bladder  neck,  and  the  apex  is  fixed  to  the 
urogenital diaphragm. The prostatic urethra traverses the gland. The verumontanum is a 
longitudinal ridge in the prostatic apex on which the ejaculatory ducts open. The prostate 
is  related superiorly and posteriorly to the seminal vesicles. The ampullae of the vas 
deferens run medial to the seminal vesicles along the posterior surface of the prostate. 
Anteriorly, the fibrous capsule thickens at the level of the apex to form the puboprostatic 
ligaments,  which attach the prostate  to the back of  the symphysis  pubis.  The dorsal 
venous complex (i.e. Santorini’s plexus) runs along the puboprostatic ligaments.  The 
prostate  gland  lies  beneath  the  endopelvic  fascia.  Posteriorly,  the  2  layers  of 
Denonvillier’s fascia separate the prostate from the rectum. The rectourethralis muscle 
attaches the rectum to the prostatic apex.
A rich plexus of veins encompasses the prostate gland between the true fibrous 
capsule  of  the gland and the lateral  prostatic  fascia;  these  are  visible  landmarks  on 
sonograms.  The  neurovascular  bundles  run  craniocaudally  along  the  posterolateral 
aspects of the prostate. The prostate gland is supplied by the prostatic artery, which is 
usually a branch of the inferior vesical artery. The prostatic artery is divided into an 
urethral branch, which supplies the adenoma, and a capsular branch. Venous drainage 
from the prostate moves into the Santorini’s plexus and eventually into the internal iliac 
vein.  The  prostatic  venous  plexus  communicates  freely  with  the  extradural  venous 
plexus  (i.e.,  Batson plexus),  which is  thought  to  be  factor  in  the  spread of  prostate 
cancer. Initially, lymphatic drainage of the prostate is into the obturator lymph nodes 
and into the hypogastric chain.
The nerve supply to the prostate is both sympathetic, from the hypogastric plexus 
(L1-2), and parasympathetic, from the pelvic nerve (nervi erigentes (S2-S4). Although 
the cavernous nerves run along the posterior aspect of the prostate, the 2 distinct areas 
from which prostatic nerves leave the gland are thought to be the superior and inferior 
pedicles. These areas are the first sites of extraprostatic spread of cancer.
Internal Architecture and Anatomy of the Prostate
According to the classic work by McNeal, the prostatic urethra, which is the main 
reference point of the prostate, divides the gland into an anterior fibromuscular stroma 
and a posterior glandular organ. The urethra angulates 35° anteriorly in the proximal 
portion of the prostate. The ejaculatory ducts run in the same plane as the distal prostatic 
urethra to join the verumontanum. Lowsley's concept  of a 5-lobed prostate has been 
replaced by McNeal's concept of zonal architecture. The prostate has 4 glandular zones, 
each with their own ductal system. The peripheral zone, transition zone, and periurethral 
glands have similar histological appearance and are derived from the urogenital sinus. 
However, the central zone is histologically distinct  and is derived from mesonephric 
tissues (i.e., wolffian tissue).
Peripheral zone
The  peripheral  zone  constitutes  almost  75%  of  the  normal  prostate  gland.  It 
occupies  the  distal  prostate  gland,  the  area  around  the  urethra  distal  to  the 
verumontanum. Their ducts drain distal to the verumontanum. Approximately 70% of 
carcinoma of the prostate (CAP) arise in this zone.
Central zone
The central zone constitutes 25% of the normal prostate and occupies the part of 
the prostate behind the proximal prostatic urethra. The ejaculatory ducts traverse through 
the central zone. Approximately 5-10% of CAP arise in this zone.
Transition zone
The transition zone makes up approximately 5-10% of the normal prostate gland. 
The transition zone lies on either side of the proximal prostatic urethra lateral to the 
internal sphincter. Approximately 20% of CAP cases arise in the transition zone.
Periurethral glands
The periurethral glands comprise less than 1% of the glandular tissue.  Anterior 
fibromuscular stroma
The anterior part  of the prostate is composed mainly of fibromuscular stroma, 
which  is  continuous  with  detrusor  fibres.  Toward  the  apex  of  the  gland,  this 
fibromuscular  tissue  blends  with  striated  muscle  from  the  levator.  Puboprostatic 
ligaments also blend with this area.
Invaginated extraprostatic space
As  the  ejaculatory  ducts  enter  the  prostate  posteriorly,  an  invaginated 
extraprostatic space (IES) surrounds them and invaginates into the prostate.  The IES 
surrounds the ejaculatory ducts, ends at the verumontanum, and communicates with the 
periurethral space. In 1989, Lee first introduced the concept that invasion of the IES may 
be  the  first  sign  of  extraprostatic  extension  of  prostate  cancer  and an  early  sign  of 
invasion  of  seminal  vesicles22.  In  2005,  Amin  et  al  evaluated  the  pathological 
significance of the invasion of IES in 80 patients with prostate cancer and concluded that 
IES involvement was consistently seen in cases with seminal vesicle invasion.23 
Bladder neck and the internal sphincter
The  internal  sphincter  runs  from  the  bladder  neck  to  the  level  of  the 
verumontanum.  The  smooth  muscle  fibres  of  the  sphincter  are  continuous  with  the 
superficial  layer  of  the  trigone.  In  healthy  males,  the  bladder  neck and the  internal 
sphincter  are  closed.  In  males  with  a  neurogenic  bladder,  the  bladder  neck and the 
prostatic  urethra  are  wide  open,  and  some  investigators  have  used  transrectal 
ultrasonography  (TRUS)  to  monitor  the  lower  urinary  tract  in  patients  with  spinal 
injuries. 
Pathophysiology and Natural History of prostate cancer25
Pathophysiology 
Prostate cancer develops when the rates of cell  division and cell  death are no 
longer  equal,  leading  to  uncontrolled  tumour  growth.  Following  the  initial 
transformation event, further mutations of a multitude of genes, including the genes for 
p53 and retinoblastoma, can lead to tumour progression and metastasis.  Most  (95%) 
prostate cancers are adenocarcinomas arising from the prostatic gland acini.
Approximately 4% of cases of prostate cancer have transitional cell morphology 
and are thought to arise from the urothelial lining of the prostatic urethra. Few cases 
have neuroendocrine morphology. When present,  they are believed to arise from the 
neuroendocrine  stem  cells  normally  present  in  the  prostate  or  from  aberrant 
differentiation programs during cell transformation.
Of prostate cancer cases, 70% arise in the peripheral zone, 15-20% arise in the 
central  zone,  and  10-15%  arise  in  the  transitional  zone.  Most  prostate  cancers  are 
multifocal, with synchronous involvement of multiple zones of the prostate, which may 
be due to clonal and nonclonal tumours.
Natural history
The natural history is still relatively unknown, and many aspects of progression 
are poorly understood. Symptoms or abnormal DRE findings in the pre-PSA era brought 
only 40-50% of patients with prostate cancer to medical attention, and these patients 
usually had locally advanced disease. The advent of PSA testing has helped to identify 
patients with less-advanced, organ-confined disease.
In fact, the pendulum has shifted to the point that certain members of the urologic 
community  feel  that  active surveillance,  also known as expectant  management,  may 
have a role. Twenty-year outcome data from Connecticut confirm that mortality rates 
due to tumours with a Gleason score of 2-4 was less than 7%.25 Urologists at Johns 
Hopkins University advocate active surveillance in patients with a PSA density of less 
than 0.1 ng/mL, with no adverse pathologic findings on needle biopsy, and with tumours 
with a Gleason score of 6 that are smaller than 3 mm.
Evidence suggests that most prostate cancers are multifocal and heterogeneous. 
Cancers can start in the transitional zone or, more commonly, the peripheral zone. When 
these cancers are locally invasive, the transitional-zone tumours spread to the bladder 
neck, while the peripheral-zone tumours extend into the ejaculatory ducts and seminal 
vesicles. Penetration through the prostatic capsule and along the perineural or vascular 
spaces occurs relatively late.
The mechanism for distant metastasis is poorly understood. The cancer spreads to 
bone early, occasionally without significant lymphadenopathy. Currently, 2 predominant 
theories have been proposed for spread—the mechanical theory and the seed-and-soil 
theory. The mechanical theory involves direct spread through the lymphatics and venous 
spaces into the lower lumbar spine. Advocates of the seed-and-soil theory believe that 
tissue factors that allow for preferential growth in certain tissues, such as the bone, must 
be present.  Lung, liver,  and adrenal metastases have also been documented. Specific 
tissue growth factors and extracellular matrices are possible examples.
The doubling time in early-stage disease is as slow as 2-4 years, but this changes 
as  the  tumour  grows and becomes  more  aggressive.  Larger  tumours  usually  have  a 
higher Gleason grade and a faster doubling time.
Natural history by stage
T1a - Progression over 10 years (uncommon) 
T1b - Tumour-related death rate of 10% in 10 years 
T2 - Ten-year metastasis-free survival rate of 81% with grade 1, 58% with grade 2, and 
26% with grade 3 
T3 - Lymph node metastasis at presentation in 50% and approximately 25% rate of 10-
year disease-free survival
The  natural  history  of  clinically  localized  disease  varies,  with  lower-grade 
tumours  having  a  more  indolent  course,  while  some  high-grade  lesions  progress  to 
metastatic  disease  with  relative  rapidity.  Several  studies  have  examined  the  cancer-
specific  and quality-of-life  outcomes associated with a  watchful-waiting approach to 
localized disease. Albertsen et al monitored patients who received no initial treatment 
for prostate cancer.25 As disease progression occurred, many received anti-androgens. 
Men  with  poorly  differentiated  tumours  lost  6-8  years  of  life,  while  those  with 
moderately differentiated tumours lost 4-5 years. Of all men monitored for 10 years, 
40% died of causes other than prostate cancer. This study was performed prior to PSA 
screening. 
Graversen et  al  compared watchful  waiting with radical  prostatectomy.26 They 
found no overall difference in survival, but they did find that a high Gleason score was 
associated with poor survival in both groups. Chodak et al confirmed this finding by 
analyzing 6 studies and finding a 34% survival rate associated with grade 3 tumours 
versus an 87% disease-specific survival rate associated with grade 1 and 2 tumors.27 The 
metastasis-free survival rate also significantly dropped as the grade progressed from 1 to 
3. 
Johansson et al (2004) reported their recent update on a population-based cohort 
study with a mean observation period of 21 years28. Prostate cancer specific mortality 
increased from 15 deaths per 1000 person-years during the first 15 years to 44 deaths per 
1000 person-years beyond 15 years of follow-up.
Taken together, these data suggest that, although most prostate cancers diagnosed 
at  an  early  stage  have  an  indolent  course,  local  tumour  progression  and  aggressive 
metastatic  disease  may  develop  in  the  long term.  In  addition,  these  findings  would 
support  early  radical  treatment,  notably  among  patients  with  an  estimated  life 
expectancy exceeding 15 years.
Detection of prostate cancer
The histologic diagnosis of prostate cancer is made, in the majority of cases, by 
prostate  needle  biopsy.  Prostate  cancer  rarely causes  symptoms until  it  is  advanced. 
Although there  is  controversy  regarding the  benefits  of  early  diagnosis,  it  has  been 
demonstrated  that  an  early  diagnosis  of  prostate  cancer  is  best  achieved  using  a 
combination  of  DRE  and  PSA.  Transrectal  ultrasound  (TRUS)-guided,  systematic 
needle biopsy is the most reliable method, at present, to ensure accurate sampling of 
prostatic tissue in men considered at high risk for harbouring prostatic cancer on the 
basis of DRE and PSA findings.
The presence of systemic symptoms (e.g., bone pain, renal failure, anaemia) as a 
result of prostate cancer suggests locally advanced or widely metastatic disease. Growth 
of  prostate  cancer  into  the  urethra  or  bladder  neck  can  result  in  obstructive  (e.g., 
hesitancy,  decreased  force  of  stream,  intermittency)  and  irritative  (e.g.,  frequency, 
nocturia,  urgency,  urge  incontinence)  voiding  symptoms.  Impotence  can  be  a 
manifestation of prostate cancer that has spread outside the prostatic capsule to involve 
the branches of the pelvic plexus (neurovascular bundle)
The routine use of DRE and PSA testing in asymptomatic men as a means of 
reducing  prostate  cancer  mortality  by  earlier  detection  and  treatment  remains 
controversial 29, 30.
The  U.S.  Preventive  Services  Task  Force  concluded  that  the  evidence  is 
insufficient to recommend for or against routine screening for prostate cancer using PSA 
testing  or  DRE.  The  American  Cancer  Society  20 and  the  American  Urological 
Association recommended that prostate cancer screening with PSA and DRE be offered 
to all men older than 50 years and that the risks and benefits of screening be discussed 
with the patient.
The  PLCO  trial  was  designed  to  address  whether  or  not  screening  reduced 
prostate  cancer  mortality  given  the  practices  of  diagnosis  and  treatment  in  the 
community. Follow-up biopsies for a positive screen and specific treatments for prostate 
cancer are not mandated in this trial. Pinsky et al  reported low follow-up biopsy rates 
after a positive screen in the PLCO trial, and whether this will compromise the ability of 
the trial to demonstrate a screening effect is controversial. 31 The PLCO has a calculated 
power of 90% to show a mortality reduction of 20% in the screened population if the 
compliance rate is 90% and the contamination rate is 20% 32
In the ERSPC, recruitment of 165,000 men to the core age group of 55 to 69 years 
will have a power of 86% to show a 20% to 25% mortality reduction in 2008 if the 
contamination rate is 20% 32
Digital Rectal Examination 
Before the availability of PSA testing, physicians relied solely on DRE for early 
detection of prostate cancer.  DRE is a test  with only fair  reproducibility even in the 
hands  of  experienced  examiners  that misses  a  substantial  proportion  of  cancers  and 
detects most cancers at a more advanced pathologic stage, when treatment is less likely 
to be effective. 9 In both screened and unscreened populations, DRE misses 23% to 45% 
of the cancers that are subsequently found with prostatic biopsies done for serum PSA 
elevations11. Results from a randomized trial of prostate cancer screening demonstrated 
that DRE alone resulted in detection of 56% of 473 cancers, and 17% of the 473 cancers 
would have been missed by PSA-based screening alone. 33
PSA improves the positive predictive value (i.e., the proportion of men with a 
positive test who actually have disease) of DRE for cancer. The positive predictive value 
of  DRE in  contemporary  series  increases  directly  with  the  PSA level.  The  positive 
predictive value of DRE also depends on age and race  33. In a screened population of 
men  with  suspicious  DREs  and  PSA  levels  less  than  4  ng/mL,  Carvalhal  and 
colleagues34 found that  black race and older  age were associated with higher cancer 
detection rates. Schroder and associates evaluated a screened population and found that 
the positive predictive value of DRE ranged from 4% to 11% in men with PSA levels of 
0 to 2.9 ng/mL and from 33% to 83% in men with PSA levels of 3 to 9.9 ng/mL or 
more. 33 
Some investigators have suggested that the value of DRE for screening at PSA 
levels  below 3.0 ng/mL is  limited.  However,  because of  the risk  of  prostate  cancer 
among men with abnormalities on DRE and the simplicity of the examination,  most 
urologists use PSA and DRE together for prostate cancer detection. 33 
Prostate-Specific Antigen (PSA or hK3) 
The most notable marker in the evaluation of prostate cancer is hK3, also known 
as PSA. It  was first  identified and purified in the late 1970s,  but widespread use in 
clinical urology did not occur for another decade. 35, 36 PSA is a 33-kD glycoprotein that 
acts as a serine protease. The ectopic expression of PSA has been reported in smaller 
concentrations in the tissue of malignant breast tumours, normal breast tissue, female 
serum, and adrenal and renal carcinomas36; however, for practical and clinical purposes 
PSA  is  organ  specific,  primarily  produced  by  the  prostatic  luminal  epithelial  cells. 
Although  it  is  organ  specific,  PSA  is  not  cancer  specific,  as  demonstrated  by  the 
substantial  overlap  in  values  between  men  with  benign  versus  malignant  prostatic 
diseases. 37
The function of this androgen-regulated protease is to liquefy semen through its 
action  on  the  gel-forming  proteins  semenogelin  and  fibronectin  within  the  semen 
following ejaculation  38.  PSA is normally found in low concentration in sera (ng/mL). 
Within sera, PSA circulates in both bound and unbound forms.  Most PSA in sera is 
bound or complexed to the antiproteases ACT and macroglobulin (MG) 38. Binding of 
free  PSA  to  ACT  inactivates  the  protease,  but  the  complex  PSA-ACT  remains 
immunodetectable  by  current  assays  38.  Binding  of  PSA  to  MG  still  allows  some 
proteolytic  activity  but  renders  the  PSA-MG complex  undetectable  by  most  current 
assays 38. Free PSA without proteolytic activity is probably rendered inactive within the 
prostatic epithelial cell before release into the sera. This free inactive PSA does not form 
complexes with antiproteases, circulates unbound in sera, and is immunodetectable by 
current  assays.  The  concentrations  found  in  seminal  plasma  range  from 0.5  to  5.0 
mg/mL, whereas the normal serum concentration in men aged 50 to 80 years without 
prostatic disease ranges between 1.0 and 4.0 ng/mL 39. 
PSA is  probably  cleared  from the  blood  through  the  liver  as  the  size  of  the 
complexed structure is too large for glomerular filtration.  The serum half-life of PSA, 
calculated after removal of all prostate tissue, is 2 to 3 days. 36 Uncomplexed PSA is 
cleared from the serum within 2 to 3 hours and is probably excreted by the kidney 
because of its smaller size  or cleared as a result of formation with new complexes with 
antiproteases.
Prostate cancer cells do not necessarily make more PSA than do normal prostate 
cells,  and  elevated  serum  levels  are  probably  a  result  of  cancer  progression  and 
destabilization of the prostate histologic architecture36   
PSA expression is strongly influenced by androgens. In men without BPH, the 
rate of change in PSA is 0.04 ng/mL per year, compared with 0.07 to 0.27 ng/mL per 
year in men with BPH who are between the ages of 60 and 85 years. 40 
The  loss  of  the  barrier  afforded  by  the  basal  layer  and  basement  membranes 
within the normal gland can occur in the setting of prostate disease (BPH, prostatitis, 
prostate cancer) and with prostate manipulation (prostate massage, prostate biopsy) 36. 
Prostatic  inflammation  (acute  and  chronic)  and  urinary  retention  can  cause  PSA 
elevations to variable degrees. Prostatic trauma such as occurs after prostatic biopsy can 
result in a leak of PSA into the circulation that may require more than 4 weeks for return 
to baseline values. Even DRE as performed in an outpatient setting can lead to increases 
in serum PSA. 
Prostate-directed treatment (for both BPH and cancer) can lower serum PSA by 
decreasing  the  volume of  prostatic  epithelium available  for  PSA production  and by 
decreasing  the  amount  of  PSA  produced  per  cell.  Manipulation  of  the  hormonal 
environment for treatment of cancer and BPH can lead to reductions in serum PSA. 
Finasteride (5 mg) and other 5α-reductase inhibitors for treatment of BPH have been 
shown to lower PSA levels by an average of 50% after 6 months of treatment41. 
Clinical Use of Serum Prostate-Specific Antigen Levels 
Early studies established the reference range of 0 to 4.0 ng/mL to define normal 
serum PSA levels. This level was obtained using the Tandem-R PSA assay (Hybritech, 
San Diego, CA) among a cohort of healthy men and demonstrated that healthy men 40 
years old and younger and 97% of men older than 40 years have PSA levels equal to or 
less than 4.0 ng/mL. Although the PSA threshold of 4 ng/mL has been most commonly 
used, the PSA threshold that most efficiently balances the dual goal of reducing cancer 
mortality  and reducing unnecessary testing (PSA measurements  and biopsies)  is  not 
known. Many studies have made an effort to evaluate other thresholds to maximize the 
positive biopsy rate of PSA-based screening. 
Gann and co workers  42  evaluated the ability of a single PSA measurement to 
predict  the  later  development  of  prostate  cancer  among  men  and  found  that  the 
maximum  validity  occurred  at  a  PSA  threshold  of  3.3  ng/mL.  Determination  of 
sensitivity and specificity at given PSA thresholds does not provide information on the 
biologic characteristics of the cancers detected.
Using  a  single  cut  off   PSA  value  for  all  men  may  risk  exclusion  of  an 
unacceptably  high  number  of  patients  with  clinically  significant  early-stage  disease; 
some men  with  PSA values  less  than  4.0  ng/mL may  harbour  clinically  significant 
organ-confined cancer. Catalona and associates detected prostate cancer in 22% (73 of 
332) of a group of men who underwent biopsy at PSA levels of 2.6 to 4.0 ng/mL and 
had benign prostate examinations. 43
Early  studies  recognized  that  the  positive  predictive  value  of  PSA testing  for 
cancer detection increased from 12% to 32% for PSA levels of 4 to 10 ng/mL and as 
high as 60% to 80% for levels above 10 and 20 ng/mL 43  Thus, men with PSA levels 
greater than 10 ng/mL and benign DRE have up to a 60% likelihood of being diagnosed 
with cancer and are unlikely to benefit from further improvement of PSA sensitivity and 
specificity.  These  percentages  are  even more  pronounced  for  levels  greater  than  20 
ng/mL or when DRE is suspicious for prostate cancer7. 
For men with PSA levels between 4 and 10 ng/mL, and more recently 2.5 to 10 
ng/mL,  the  specificity  of  cancer  detection  has  been  more  challenging.  Cancers 
discovered within this range are often earlier in stage, and potentially more curable, yet 
might also represent “insignificant,” potentially non–life-threatening tumours. 
Transrectal Ultrasonography Technique
Preparation, positioning, and contraindications
More  than  80%  of  urologists  administer  an  enema  prior  to  transrectal 
ultrasonography (TRUS) and prostate biopsy, but some authors feel this is unnecessary.
More than 90% of urologists administer oral agents for prophylactic antibiotic 
coverage. A total of 11 different antibiotics with 20 different dosages and durations of 
treatment,  ranging from 1-17 days,  have been reported.  Increasing support  has been 
garnered for single-dose prophylaxis in patients with uncomplicated medical conditions. 
A fluoroquinolone antibiotic prior to the procedure and a second dose 12 hours later is 
the  protocol  most  commonly  recommended for  antibiotic  coverage.  In  patients  with 
prosthetic  implants  or  valvular  heart  disease,  additional  prophylaxis  with  1  g  of 
intramuscular  ampicillin  (or  1  g  IV  vancomycin  in  patients  who  are  allergic  to 
penicillins) and 80 mg of intramuscular gentamicin is recommended.
Positioning can be either left lateral, lithotomy, or knee-elbow.
Contraindications  to  biopsy  include  an  acute  painful  perianal  disorder  and 
hemorrhagic  diathesis.  Patients  should  be  discouraged  from  taking  aspirin  or  non-
steroidal  anti-inflammatory drugs for  10 days prior  to  the procedure,  but  recent  use 
should not be considered an absolute contraindication to biopsy.
Local anaesthesia and the procedure
Although the procedure was performed without any infiltrative anesthesia in the 
past it is a common practice to use lidocaine infiltration in the periprostatic area.  In 
2001, Pareek et al described a technique of periprostatic nerve blockade.44 They injected 
2.5 ml of lidocaine on each side at the prostate base at the junction of the prostate and 
the seminal vesicle (using a 5-in 22-gauge spinal needle through the ultrasound probe). 
In a randomized, double-blind, placebo-controlled study, they showed significant pain 
control during and after biopsy. Alavi et al compared the efficacy of intrarectal lidocaine 
gel  with  that  of  periprostatic  nerve  block  and  concluded  that  the  nerve  block  was 
superior for pain control. Using this technique, saturation biopsies, with up to 20 cores, 
could be performed.
In  2005,  Mutaguchi  et  al  reported  a  comparison  of  2  techniques  of  local 
anesthesia  for  prostate  biopsy.45 In  the  periprostatic  block  technique,  5  ml  of  1% 
lidocaine was injected via a 7-in, 22-gauge spinal needle into the region of the prostatic 
vascular pedicle just lateral to the junction of seminal vesicles and the prostate.  The 
needle is slowly withdrawn to the prostatic apex, and an additional 5 ml of lidocaine is 
injected at the apex. In the intraprostatic block technique, 10 ml of 1% lidocaine was 
injected  into  2-3  sites  of  each  prostate  lobe.  In  this  study,  the  intraprostatic  block 
provided superior pain control during the prostate biopsy.
Technique of TRUS of prostate
Currently, the most widely used probe is a 7-MHz transducer within an endorectal 
probe, which can produce images in both the sagittal and axial planes. Scanning begins 
in the axial plane, and the base of the prostate and seminal vesicles are visualized first. A 
small amount of urine in the bladder facilitates the examination. Seminal vesicles are 
identified bilaterally, with the ampullae of the vas on either side of the midline. The 
seminal  vesicles are convoluted cystic structures that  are darkly anechoic.  Men who 
have abstained from ejaculation for a long period may have dilated seminal vesicles.
Next,  the  base  of  the  prostate  is  visualized.  The  central  zone  comprises  the 
posterior part of the gland and is often hyperechoic. The mid gland is the widest portion 
of the gland. The peripheral zone forms most of the gland volume. Echoes are described 
as isoechoic and closely packed. The transition zone is the central part of the gland and 
is hypoechoic. The junction of the peripheral zone and the transition zone is distinct 
posteriorly and is characterized by a hyperechoic region, which results from prostatic 
calculi  or corpora amylacea. The transition zone is often filled with cystic spaces in 
patients with benign prostatic hyperplasia (BPH).
Scanning at the level of the verumontanum and observing the Eiffel tower sign 
(anterior shadowing) help to identify the urethra and the verumontanum. The prostate 
distal to the verumontanum is composed mainly of the peripheral zone. The capsule is a 
hyperechoic  structure  that  can  be  identified  all  around  the  prostate  gland.  Several 
hypoechoic rounded structures can be identified around the prostate gland. These are the 
prostatic venous plexi. The position of the neurovascular bundles can often be identified 
by  the  vascular  structures.  Imaging  in  the  sagittal  plane  allows  visualization  of  the 
urethra. The median lobes of the prostate are often visualized.
Volume measurement
Volume  assessment  of  the  prostate  is  an  important  and  integral  part  of  this 
procedure. Several formulas have been used, the most common of which is the ellipsoid 
formula,  which requires measurement of 3 prostate dimensions.  Dimensions are first 
determined in the axial plane by measuring the transverse and anteroposterior dimension 
at the estimated point of widest transverse dimension. The longitudinal  dimension is 
measured  in  the  sagittal  plane  just  off  the  midline  because  the  bladder  neck  often 
obscures the cephalad extent of the gland. The ellipsoid volume formula is then applied, 
as follows: 
Volume = height X width X length X 0.52
Biopsy
Biopsies are best performed with a spring-driven needle core biopsy device (or 
biopsy gun), which can be passed through the needle guide attached to the ultrasound 
probe. Most instrumentation provides optimal visualization of the biopsy needle path in 
the sagittal plane. In general, 18-gauge needles are used, and the tips of the needles are 
etched with small ridges or pits to render them more echogenic. Sonograms should be 
superimposed with a ruled puncture trajectory that corresponds to the needle guide of 
the probe, which allows anticipation of the needle path.
Directed  biopsies  are  obtained  from  any  area  deemed  as  suggestive  (i.e., 
hyperechoic)  based  on ultrasonographic  findings  or  based  on palpable  abnormalities 
after digital rectal examination. Because the incidence of nonpalpable isoechoic prostate 
tumours is high, limiting biopsy sites to either ultrasonographically hypoechoic lesions 
or to areas of palpable abnormality tends to miss many malignancies.
Obtaining separate biopsy samples from each sextant of the prostate, improves the 
odds of sampling clinically inapparent tumours. Originally, these biopsy sites included 
the midlobe parasagittal plane at the apex, the mid gland, and the base, bilaterally. Many 
authors subsequently recommended that (1) these 6 biopsy samples be obtained from the 
lateral  third of  each lobe rather  than from the mid lobe or  that  (2)  2  lateral  biopsy 
samples be obtained from each lobe in addition to the original sextant samples (termed 
the  10-biopsy  scheme).  Obtaining  even  larger  numbers  of  biopsy  cores  has  been 
recommended by some authors to increase the diagnostic sensitivity.
Complications  of  prostate  biopsy  include  hematuria,  rectal  bleeding, 
hematospermia,  urosepsis,  and  perineal  pain.  Although  most  of  these  complications 
subside within 48-72 hours, patients should be warned that hematospermia can last for 
3-4 weeks. In rare cases (<1%), patients develop bacteremia that requires hospitalization 
and  administration  of  intravenous  antibiotics.
Indications for Prostate Biopsy 
Before  TRUS  improvements  and  serum  PSA  testing  became  widespread, 
clinicians relied mainly on digital rectal examination to establish a suspicion of prostate 
cancer and performed digitally directed lesional biopsies.  Today, PSA-based screening 
of asymptomatic men has resulted in the adaptation of TRUS biopsy as the standard of 
care  for  routine  prostate  biopsy. The  presence  of  focal  nodules  on  digital  rectal 
examination still  will  prompt a biopsy using the TRUS technique regardless of PSA 
levels. TRUS-directed prostate needle biopsy remains the gold standard for diagnosis of 
prostate cancer. 
Early  prostate  cancer  detection  has  been  markedly  improved  by  PSA-based 
screening programs. These initiatives have been shown to significantly increase the rate 
of  organ-confined,  and  potentially  curable,  disease46.  Currently,  most  clinicians 
recommend  biopsy  once  a  patient's  serum  PSA  rises  above  4.0  ng/mL,  although 
significant  research  efforts  are  ongoing  to  identify  the  optimal  PSA  threshold  to 
recommend prostate biopsy in the asymptomatic patient. Evidence for lowering the PSA 
threshold from work by Catalona's group showed higher rates of organ-confined disease 
at the time of radical retropubic prostatectomy in men sampled with PSAs in the 2.6- to 
4.0-ng/mL range47. These findings have led many urologists to now recommend prostate 
biopsy to men younger than 60 years of age once their PSA level rises above 2.5 ng/mL. 
Despite this downward shift in the PSA cut off for younger men, there remains a general 
trend toward allowing older men (70 years or older) to have slightly higher “normal” 
PSAs, in the range of 5.5 to 6.5 ng/mL, although this is not universally accepted.48
Adjuncts  to  serum  PSA  testing  include  measuring  the  free:  total  PSA,  PSA 
velocity,  PSA density  (PSAD), and PSAD of the transition zone (PSAD-TZ)  49.  For 
patients with a serum PSA value between 4.0 and 10.0 ng/mL, using a percentage of free 
PSA  threshold  of  less  than  25%  detected  95%  of  cancers  while  eliminating  20% 
unnecessary  biopsies,  and  within  this  group  the  risk  of  prostate  cancer  increased 
dramatically as the percentage of free PSA level declined. 50
Regardless of initial PSA value, a PSA velocity greater than 0.75 to 1.0 ng/mL per 
year is frequently associated with prostate cancer and warrants biopsy 49,  whereas an 
elevated  PSAD and  PSAD-TZ  have  both  been  shown  to  increase  the  likelihood  of 
diagnosing prostate cancer on repeat biopsy. 
Contraindications to Prostate Biopsy 
Significant  coagulopathy,  painful  anorectal  conditions,  severe 
immunosuppression, and acute prostatitis are all contraindications to prostate biopsy.
Sextant Biopsy 
The  original  sextant  biopsy  scheme  (one  core  from the  base,  mid,  and  apex 
bilaterally)  significantly  improved  cancer  detection  over  digitally  directed  biopsy  of 
palpable nodules and ultrasound-guided biopsy of specific hypoechoic lesions 51. Taken 
in the parasagittal plane these cores sampled a portion of the PZ but also included a 
significant  amount  of  tissue  from  the  TZ,  with  subsequent  studies  of  radical 
prostatectomy specimens demonstrating that the vast majority of adenocarcinomas arise 
in the posterolateral PZ52, thus explaining some of the false-negative results of standard 
sextant biopsy.
Extended Core Biopsy Techniques 
Modifications  to  the  standard  sextant  biopsy  scheme  have  focused  on  the 
importance  of  laterally  directed  cores 53.  Numerous  groups  have  published  series 
showing improved cancer detection rates by incorporating additional laterally directed 
cores into the standard systematic sextant technique, ultimately taking anywhere from 8 
to 13 cores 13, 54, 49. In a prospective study of 483 patients Presti and coworkers 30found 
that adding laterally directed cores from the base and mid gland bilaterally improved 
cancer detection from 80% with standard sextant to 96% with this 10-core scheme (only 
4% of cancers were detected on the lesion directed or TZ biopsy). At present, 6 cores are 
considered inadequate for routine prostate biopsy for cancer detection. 
Increasing Prostate Cancer Detection Rates with Extended Core Biopsy Protocols 
TZ and SVs are not routinely sampled because these regions have been shown to 
have  consistently  low yields  for  cancer  detection  at  initial  biopsy,  55,56 but  TZ  and 
anteriorly  directed  biopsies  may  occasionally  prove  necessary  to  diagnose  prostate 
cancer  in  those  patients  with  persistently  elevated  PSA  levels  and  prior  negative 
biopsies57. However, there may be a role for TZ biopsies in men with gland size of more 
than 50 ml, with an additional yield of 15% cancer detection in these larger prostates 58. 
Seminal vesicle biopsy is not routinely performed unless there is a palpable abnormality, 
with some authors recommending SV biopsy when the PSA value is greater than 30 or if 
brachytherapy is being considered. 
Study Cores Detection rate
Eskew et al, 1997 59
6 26.1%
13 40.3%
Naughton et al, 2000 60
6 26%
12 27%
Presti et al, 2000 13 6 33.5%
8 39.7%
10 40.2%
Babaian et al, 2000 61 6 20%
11 30%
Repeat and Saturation Prostate Biopsy 
Physicians are frequently presented with the dilemma of a patient who has had 
one or more negative prostate biopsies yet continues to have an elevated PSA value or 
abnormal digital rectal examination of concern for prostate cancer. Often these patients 
have  undergone  multiple  biopsies  despite  the  well-documented  decline  in  cancer 
detection with each successive biopsy  62.  Keetch and coworkers  63 reported an initial 
positive biopsy rate of 34% in 1136 men from their PSA-based prostate cancer screening 
program. Cancer detection rates then fell to 19%, 8%, and 7% on biopsy 2, 3, and 4, 
respectively.  These  findings  were  confirmed  by  results  from the  European  Prostate 
Cancer Detection Study. In this cohort of 1051 men with PSA values between 4.0 and 
10.0 ng/mL the initial cancer detection rate with sextant biopsy was 22%. Positive cores 
were then found in only 10%, 5%, and 4% of patients on subsequent biopsies 2, 3, and 
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These diminishing returns coupled with improved cancer detection rates on initial 
biopsy with extended core protocols have led some researchers to examine “saturation 
biopsy” techniques in this difficult  subset of patients.  In a study of 57 men with an 
average  of  two prior  negative  sextant  biopsies,  a  cancer  detection  rate  of  30% was 
obtained with an average of 22.5 cores per patient 64. Similar protocols from the Mayo 
Clinic65 demonstrated improved cancer detection rates. A drawback to these techniques 
is that additional anesthetic requirements often require these “saturation” biopsies to be 
performed in a hospital setting. 
Ramey  et  al,  suggested  that  equally  improved  cancer  detection  rates  can  be 
achieved in this setting utilizing contrast medium–enhanced TRUS (CE-TRUS) and a 
targeted  biopsy  protocol  in  an  outpatient  setting  with  only  10  cores  66,  thereby 
minimizing the morbidity and costs associated with saturation biopsies. The use of the 
free and total PSA may also allow classification of patients into low probability or high 
probability of having prostate cancer with a PSA level less than 10 ng/mL and determine 
the need for additional prostate biopsy after an initial negative result 50
Advanced ultrasonographic techniques for prostate imaging 
Colour and Power Doppler TRUS 
Colour Doppler imaging is based on the frequency shift in the reflected sound 
waves from the frequency of insonation and thus depicts the velocity of blood flow in a 
directionally dependent manner.  Colour assignment is based on the direction of blood 
flow related to the orientation of the transducer receiving the signal; flow toward the 
transducer is depicted in shades of red and flow away in shades of blue; the colour is not 
specific for arterial or venous flow. Power Doppler imaging (also known as enhanced 
colour  Doppler,  colour  amplitude  imaging  [CAI],  or  colour  angiography)  utilizes 
amplitude shift to detect flow in a velocity and directionally independent manner 67. The 
advantages of power Doppler imaging are its ability to detect slower flow and to have 
less reliance on the Doppler angle,  making it  more suitable for detection of prostate 
cancer neovascularity. Although power Doppler imaging offers improved sensitivity to 
small amounts of flow, neither modality has yet proved itself superior to the other for 
cancer detection.
In a study by Maruzzi et al, 68 222 biopsies performed on 71 patients between 
1997 and 1999 were considered, which led to a diagnosis of neoplasm in 36 patients. Of 
the 84 biopsies that revealed prostate adenocarcinoma, 74 (64.3%) were correlated to 
hypoechoic  lesions  with  abnormal  flow signals  while  41  (35.6%)  showed  a  benign 
pathology (prostatitis  or  benign prostatic  hyperplasia)  (p  <  0.0011).  In  five  patients 
(13%)  who did  not  present  any  evident  lesions  at  a  first  transrectal  ultrasound,  the 
diagnosis of neoplasm was made only through biopsies targeted on areas with abnormal 
flow.  Therefore,  they  concluded  that  the  colour  Doppler  exam can  be  used  during 
prostate ultrasonography either to consolidate the diagnosis or to give a useful target in 
case of isoechoic lesions. 
 Takahashi  and colleagues69  studied a total of 108 men (mean age 67.7 years, 
range 50 to 86) with serum PSA levels of greater than 4.0 ng/mL using digital rectal 
examination  (DRE),  grey-scale  transrectal  ultrasonography  (TRUS),  and  PDU.  and 
systematic  six-core transperineal  biopsy  and additional  biopsies  for  positive  sites  on 
DRE, grey-scale TRUS, and PDU. A hypervascular site and prostate cancer on PDU was 
identified in 43 (40%) and 40 (37%) cases, respectively. The sensitivity of PDU for 
cancer  detection  was  90%,  specificity  90%,  positive  predictive  value  84%,  negative 
predictive value 94% and accuracy 90%. High test performance was also observed in 53 
cases with serum PSA levels  of  4.1 to  10 ng/mL (sensitivity  77%, specificity  88%, 
positive predictive value 67%, negative predictive value 92%, and accuracy 85%). These 
values  were  superior  or  comparable  to  those  of  DRE  and  grey-scale  TRUS. 
Inflammatory  reactions  and  prostatic  calculi  were  probable  major  causes  of  false-
positive and false-negative results on PDU, respectively. 
Okihara et al70 studied 275 men. Cancer was identified in 27% of men in Japanese 
and in 60% of American men. The sensitivity and specificity of PDI in Americans were 
significantly inferior to those in Japanese. The negative predictive value (NPV) of PDI 
was significantly higher for Japanese. 
In a significant study by Wilson et al, 71 96 patients with LUTS and PSA > 4 ng/ml 
were evaluated using PDUS before biopsy. There was a significant correlation between 
the grading system used for power Doppler and the microvessel density (MVD; PZ0 
28.61 +/- 8.97, PZ1 36.00 +/- 12.11 & PZ2 64.008 +/- 15.86; p < 0.001). There was also 
a significant difference in MVD between benign, malignant and tissue cores with atypia 
and prostatic  intra-epithelial  neoplasia  (PIN; p  < 0.001 and p < 0.018 respectively). 
There was a significant correlation between malignant tissue having a higher Gleason 
score and increased MVD (p < 0.001) Furthermore, cancer biopsies having a high flow 
PZ2 are nearly twice as likely (63.2%) to have a Gleason score of 7 or more when 
compared those having a Gleason score of less than 7 (36.8%). They concluded that it 
can be useful in the detection of prostate cancer. 
In a study by Inahara et al, 72101 men with abnormal DRE or PSA were assessed 
with TRUS with PDI. Of the 101 patients, 48 (47.5%), 42 (41.5%) and 42 (41.5%) were 
suspicious of having prostate cancer by DRE, TRUS and PDI, respectively. If prostate 
needle biopsy was avoided when PDI was negative, then PDI eliminated the need for 
biopsy in 59 of the 101 patients (rate of biopsy procedures saved: 58.4%) and missed 
only 8 (13.6%) prostate cancers. Moreover, in 63 patients with intermediate PSA (3-10 
ng/ml),  the  rate  of  biopsy  procedures  saved  by  DRE,  TRUS,  and  PDI  was  60.3%, 
65.1%, and 68.3%, respectively, and the rate of cancers missed was 26.3%, 19.5%, and 
14.0%, respectively. 34.1% of prostate cancer sites were isoechoic and hypervascular. 
On a site by site basis, PDI had better sensitivity, specificity, positive predictive value 
and negative predictive value than TRUS. In patients without abnormal DRE findings, 
on  a  site  by  site  basis,  the  sensitivities  of  TRUS and PDI were  22.9% and 34.4%, 
respectively. 
In a study by Remzi et al, 73136 men with PSA between 2.5 and 10 ng/ml (mean 
age 64 +/- 9 years, range 45-82) and a normal DRE were included. 101 underwent a first 
biopsy whereas 35 had repeat biopsy. Overall prostate cancer detection rate was 34.7% 
and 25.7% and abnormal accumulation on PD-TRUS was identified in 42.3% and 48.6% 
on first  and repeat biopsy, respectively. PD-TRUS directed biopsies were positive in 
5.7% and 11.1% on first and repeat biopsy whereas prostate cancer detection using the 
routine prostate biopsy regime was 94.3% and 88.9% on first and repeat biopsy. The 
sensitivity,  specificity,  positive predictive value (PPV) and negative predictive value 
(NPV)  of  PD-TRUS signal  alone  for  prostate  cancer  detection  on  first  biopsy  was 
82.8%, 78.8%, 87.9% and 89.7%, respectively, and 88.8%, 68.0%, 47.0% and 94.4% on 
repeat biopsy, respectively. Negative PD-TRUS signal is able to exclude most of the 
patients without prostate cancer in the PSA range of 2.5-10 ng/ml. As an additional tool 
at TRUS biopsy PD-TRUS has a high negative predictive value and may help to reduce 
the number of unnecessary biopsies.
In a study by Satoru 74et al, 108 men with serum PSA levels of greater than 4.0 
ng/mL were assessed using DRE, TRUS, and PDU. A hypervascular site and prostate 
cancer  on PDU was identified in 43 (40%) and 40 (37%) cases,  respectively.  PDU-
directed and systematic six-core biopsies could independently detect 36 and 30 cancer 
cases, respectively. The sensitivity of PDU for cancer detection was 90%, specificity 
90%, positive predictive value 84%, negative predictive value 94% and accuracy 90%. 
High test performance was also observed in 53 cases with serum PSA levels of 4.1 to 10 
ng/mL  (sensitivity  77%,  specificity  88%,  positive  predictive  value  67%,  negative 
predictive value 92%, and accuracy 85%). These values were superior or comparable to 
those of DRE and gray-scale TRUS. PDU can identify appropriate sites for biopsy and 
improve the cancer detection rate. Combined use of sextant biopsy and PDUS should be 
preferable.
Mohammd et al75 in their study concluded that, Colour-coded Doppler flow within 
the tumor and overlying capsule appears to correlate with both tumor grade and stage, 
respectively. Detection and grading of colour-coded flow within biopsy-proven cancers 
may  identify  patients  with  a  high  likelihood  of  biochemical  relapse.  Tsuneyuki 
Nakanouchi  et  al76from their  study  on 22 patients  prior  to  RP concluded that, semi 
quantitative assessment  of  Doppler  flow signals  using PDI appears  to  be of  clinical 
value as an indicator of MVD. 
Arger etal77  studied  90 patients and found that 71% of the 31 focal hypoechoic 
lesions  were  hypervascular.  Only  23% were  carcinoma.  Sauvain78 et  al  studied  323 
patients with suspected cancer. The sensitivity of PDS for prostatic cancer was 92.4% 
and  its  specificity  was  72%  (versus  87.9%  and  57.6%  for  sonography  alone 
respectively).  The  NPV  of  PDS  was  80.6%  (p<0.0001).  Targeting  area  presenting 
abnormal blood flow in any part of the prostate was useful to detect isoechoic or lesions 
in patients with first negative biopsy results. 
Halpern et al79,  in their study on 62 patients with cancer in 18 (29%) patients 
found that The positive biopsy rate for targeted biopsy (24 [13%] of 185 cores) was 
slightly higher than that for sextant biopsy (36 [9.7%] of 372 cores; P =.1). The odds 
ratio for cancer detection with targeted versus sextant cores was 1.8 (95% CI: 0.9, 3.7). 
Receiver  operating  characteristic  analysis  demonstrated  that  overall  identification  of 
positive sextant biopsy sites was close to random chance for grey-scale (area under the 
curve,  0.53),  colour  Doppler  (area under  the curve,  0.50),  and power  Doppler  (area 
under the curve, 0.47) imaging. 
Okihara et al80, in their study on a total of 170 cases, the positive biopsy rate was 
59% (40/68) in cases with HVL, compared to 1% (1/102) in cases with no HVL (p < 
0.0001). In 107 patients with serum PSA 4.1 to 10.0 ng/ml, biopsy was positive in 13 
cases (12%). The positive biopsy rate was 38% (12/32) in cases with HVL, compared to 
1% (1/75) in cases with no HVL (p < 0.0001). These results imply that HVL represents 
the neovascularity or increased perfusion of blood in the cancer lesion. 
Sakarya et al81, in their study on 36 patients calculated that the sensitivity of PDU 
was 90%, the specificity 75% and the positive predictive value 82%. Okihara et al 82  in 
their study on 107 patients found that PDI had a high sensitivity of 98% (40/41) and a 
negative predictive value of 99% (101/102). PDI could save a significant number of 
patients from undergoing unnecessary biopsies, compared with DRE and TRUS (P < 
0.001). 28 patients were studied by Franco83 and colleagues, and the sensitivity of PDUS 
was 74%, the specificity 96% and the positive predictive value 74%. 
Whereas Doppler modes showed an improved diagnosis versus grey-scale TRUS, 
45% of cancers still went unidentified by any sonographic modality. Others have shown 
increased cancer detection rates using Doppler-targeted biopsy strategies 81, but none is 
sufficiently  accurate  to  replace  systematic  biopsy  79.  Enhancements  in  the  technical 
aspects of colour Doppler TRUS, including the use of contrast agents (see later), may 
provide the necessary improvements to specifically identify cancer sites in the future. 
Multiple studies have shown that angioneogenesis and the resultant increase in 
microvessel density that occurs within foci of prostatic adenocarcinoma correlates with 
the presence of metastases84, stage of disease 84,85, and disease-specific survival. Interest 
in using colour and power Doppler TRUS to aid in prostate cancer detection stems from 
studies of radical prostatectomy specimens demonstrating that foci of adenocarcinoma 
possess  an  increased  density  of  microvessels  compared  with  surrounding  normal 
parenchyma. 86 Patients with detectable colour Doppler flow within their dominant tumor 
at the time of TRUS-guided biopsy are at a 10-fold increased risk for PSA recurrence 
after  radical  retropubic  prostatectomy  76 The  presence  of  increased  flow  was  also 
associated with higher Gleason grade, increased incidence of SV invasion, and a lower 
biochemical disease-free (bNED) survival rate versus subjects without increased flow on 
preoperative TRUS (50% vs. 96% bNED at 31 months). 
Current Doppler modalities are not able to identify the microvessels of prostate 
cancer, which are typically 10 to 15 μm in diameter. The flow signals associated with 
malignant foci detected by unenhanced colour and power Doppler imaging are due to 
detection  of  larger  feeding  vessels. 88 Intravenous  micro  bubble  ultrasound  contrast 
agents,  similar to those currently approved and used in echocardiography, have been 
infused systemically  during  grey-scale  and TRUS Doppler  imaging to  amplify  flow 
signals within the microvasculature of prostate tumours, allowing selective visualization 
of malignant foci in clinical trials 79, 88.  These intravenous “bubble” contrast agents are 
constructed with air  or  higher-molecular-weight gas agents encapsulated (albumin or 
polymer hard shell, lipid or surfactant coated) for longevity and are generally 1 to 10 
μm. 
Using  CE-TRUS  for  prospective  prostate  cancer  detection,  Halpern  and 
associates79 demonstrated an increase in sensitivity from 38% to 65% versus baseline 
unenhanced imaging,  without significantly altering specificity. Subsequent studies by 
our group and others have improved sonographic detection of malignant foci utilizing 
CE-TRUS and targeted biopsy of enhancing lesions89,  90. Imaging using micro bubble 
contrast  agents  combined  with  three  dimensional  image  reconstruction  of  enhanced 
power  Doppler  images  also  demonstrated  increased  diagnostic  accuracy.  Future 
developments  in  these  and  other  imaging  modalities  that  can  selectively  visualize 
prostate cancers based on the presence of angioneogenesis may ultimately allow more 
accurate localization of the sites of cancer. 
Other Investigational Techniques 
Artificial neural networks are another potential way to enhance TRUS images and 
identify  malignant  foci. Investigational  automated  image  analysis,  including  pattern 
recognition and artificial neural networks applied to TRUS images, may successfully 
identify lesions that cannot be seen by the human eye. 91
A new sonographic technique known as elastography may prove to be superior to 
colour Doppler imaging in the identification of malignant areas in the prostate. 92 This 
technique employs real-time sonographic imaging of the prostate at baseline and under 
varying  degrees  of  compression.  Through  computerized  calculations,  differences  in 
displacement between ultrasonic images from baseline and during compression may be 
visualized and regions with decreased tissue elasticity may be tagged as suggestive of 
malignancy. In a preliminary study of 404 cases with 151 cases positive for prostate 
cancer, the malignancy was found in 127 patients (84.1%) with real-time elastography 
directing the biopsy. 93
Endorectal  magnetic  resonance  imaging  (MRI)  and  MR  spectroscopy  as 
combined modalities might be able to guide and therefore limit the number of iterative 
biopsies  and  cores  for  patients  94.  Utilization  of  MRI  will  require  modifications  in 
instrumentation and the technique of biopsy  95. These MRI-directed biopsy techniques 
require expensive equipment that is not widely available for biopsy procedures.
MATERIALS AND METHODS
A prospective study was conducted in the time period between July 2006 and May 
2009.  All  the patients  more than 50 years  who presented to  the Urology OPD with 
LUTS with abnormal digital rectal examination and/or PSA>=4 ng/ml were evaluated 
for inclusion in the study.
Exclusion criteria
1. No consent for study
2. Persistent urinary tract infection
3. Untreated coagulopathy
After obtaining informed consent all  the patients were enrolled into the study. 
Routine  clinical  evaluation  was  done  as  per  the  proforma  and  the  findings  were 
recorded.
All  the patients  were evaluated by TRUS. On the day prior  to the procedure, 
ciprofloxacin  500mg  bd  and  metronidazole  400  mg  tds  was  prescribed,  which  was 
continued for 2 days post procedure. PC enema was given on the day of the procedure. 
Intravenous pethidine was given as analgesic if the patient did not tolerate pain.
Patients were examined using the SSD2000 System (Aloka, Japan); PDUS was 
carried out with a Power Flow Unit and 7.5 MHz broadband endoluminal probe. The 
patients  were examined in the left  lateral  decubitus position.  All  patients  underwent 
greyscale TRUS of the entire prostate gland in the sagittal plane, from the right to left 
lateral aspects of the gland and in the axial plane from the seminal vesicles to the apex. 
The size and weight of the gland were calculated from the anteroposterior, transverse 
and cranio caudal measurements (0.52 × D1 × D2 × D3). 
PDI was performed using the same ultrasound system as for conventional TRUS. 
The power Doppler gain was set to a point below the range at which blood flow in the 
neurovascular bundles was identified with no background artefact. Scanning to detect 
flow was continued for  10 min in each patient.  The vascularization of  a hypoechoic 
lesion in the PZ was evaluated by comparison with that of the area surrounding it. When 
a hypoechoic lesion contained more vessels than other PZ areas, it  was defined as a 
hypervascular area. Equivocal and isoechoic lesions were defined as hypervascular area 
when these lesions were seen as abnormal vascular areas. 
All  patients  underwent  systematic  core  biopsies  initially  at  the  hypervascular 
areas and hypoechoic areas if seen and then standard 10 core biopsy was taken from the 
prostate. 18 G (Bard Urological, Covington, GA) automatic core biopsy needles were 
used. Biopsy samples from each site were placed in separate containers of formalin and 
labelled as to the site of origin. The biopsy results were analysed statistically to evaluate 
the differential efficacy of the hypoechoic nodule and hypervascular areas.
RESULTS
A total of 129 patients were included in the study period.
75 patients (58%) had cancer detected in the biopsy
Table-1: Age group of patients
Age Group Number
<55 1(0.7%)
56-60 33(25.5%)
61-65 39(30.2%)
66-70 33(25.5%)
71-75 12(9.3%)
76-80 11(8.8%)
Grand Total 129(100%)
The mean age group of the patients was 65.63 years in the age range between 55 
and 80 years.  The most  common age group involved was between 56 and 70 years 
involving 80% of the patients. 
49 of the 129 (37%) patients had a normal DRE.
PSA value
The PSA value of the patients ranged from 3 ng / ml to 632 ng / ml with a mean value of 
41.4 ng / ml.
Table-2:  PSA group of patients
PSA Group(ng/ml) Number
<4 1(0.7%)
4--10 14(10.8%)
11--20 37(28.6%)
21-50 58(44.9%)
>50 19(15%)
Grand Total 129(100%)
Prostate volume
Table-3: Prostate volume of patients
Prostate volume Number
<25 g 55(42.6%)
26-50 g 62(48%)
>50 g 12(9.4%)
Grand Total 129(100%)
The mean prostate volume was 32.7g in the range between 12 and 155g.
Relation of cancer with various parameters
Age group
The proportion of patients who are negative for cancer are proportionately more 
in the age group 56-60 years.  The highest incidence of cancer was in the age group 
66-70 years. All the patients in the age group above 70 years had cancer. However, the 
difference in age distribution was not statistically significant.
Table-4: Relation of cancer with age group
Age Gp (Yrs) Ca present No Ca Total
<55 1 0 1
56-60 15 18 33
61-65 19 20 39
66-70 19 14 33
71-75 12 0 12
76-80 9 2 11
Grand Total 75 54 129
p-0.129
PSA level
Table-5: Relation of cancer with PSA group
PSA Gp(ng/mi) Ca present No Ca Total
<4 1 0 1
4--10 2 12 14
11--20 21 16 37
21-50 38 20 58
>50 13 6 19
Grand Total 75 54 129
p-0.02
75% of patients with PSA between 4 and 10 ng/ml were negative for malignancy. Even 
with a PSA of > 50 ng/ml had negative result for malignancy. Most of the patients with 
cancer were in the PSA range of 21-50ng/ml.
Prostate volume and Cancer
Patients with cancer are equally distributed among all the prostate sizes.
Table-6: Relation of prostate volume with cancer
Prostate vol. Ca present No Ca Total
<25 29 26 55
26-50 38 24 62
>50 8 4 12
Grand Total 75 54 129
p-0.66
DRE and tumour
Table-7: Relation of DRE with cancer
DRE Ca present No Ca Total
+ ve 56 24 80
- ve 19 30 49
Grand Total 75 54 129
p-0.004
70% of patients with positive DRE had positive biopsy.
Correlation between Hypoechoic area and carcinoma
Table-8: Relation of hypoechoic area with cancer
Hypo. area Ca present No Ca Total
Yes 47 18 65
No* 28 36 64
Grand Total 75 54 129
*- Absent hypoechoic area / negative biopsy
The  sensitivity  of  hypoechoic  nodule  in  the  detection  of  prostate  cancer  is  62.7%, 
Specificity is 66.7%, Positive Predictive value 72.3% and Negative predictive value is 
56%.
Correlation between hypervascular area and carcinoma
Table-9: Relation of hypervascular area with cancer
Hypervascularity Ca present No Ca Total
Yes 66 12 78
No* 9 42 51
Grand Total 75 54 129
*- Absent hypervascular area / negative biopsy
The  sensitivity,  specificity,  PPV,  NPV of  hypervascular  area  in  the  detection  of  ca 
prostate are 88.5%, 79.8%, 84.6%, 82.3% respectively.
Correlation between hypervascularity in hypoechoic area and cancer
Table-10: Relation of hypervascularity in hypoechoic area with cancer
Hypervascularity in 
hypoechoic lesion Ca present No Ca Total
Yes 34 1 35
No 41 53 94
Grand Total 75 54 129
The  sensitivity,  specificity,  PPV,  NPV of  hypervascularity  in  the  hypoechoic 
nodule in the detection of ca prostate are  45.3%, 98%, 97%, 56.3% respectively
Statistical comparison of parameters
Table-11: Comparison of parameters
Hypervascular
area
Hypoechoic
area
Hypervascularity 
in hypoechoic area
Sensitivity 88.5% 62.7%* 45.7%*
Specificity 79.8% 66.7% β 98%*
PPV 84.6% 72.3% β 97%¶
NPV 82.3% 56%.* 56.3%*
¶-p-Not significant, *-p<0.01, β-p<0.05 (compared with PDI)
Complications
A  total  of  16  patients  had  complications.  Febrile  UTI  was  the  most  common 
complication involving 8 patients. All were managed conservatively. 
Table-12: Complications
Complication Number
UTI 8
Retention 7
Bleeding 4
DISCUSSION
Prostate  cancer  is  the  most  common  non  cutaneous  cancer  involving  men. 
Nowadays, most of the prostate cancer is diagnosed incidentally, at least in the western 
countries. In our country most of the patients present with symptoms such as LUTS or 
other metastatic symptoms.
As the diagnostic modalities such as serum PSA and DRE have significant false 
positive  and  false  negative  rates,  histological  diagnosis  by  TRUS  guided  biopsy  is 
considered the gold standard to diagnose prostate cancer.  Though it is considered the 
primary  investigation,  it  has  only  85%  sensitivity  and  80%  specificity,  even  with 
extended core biopsy.
To increase the yield various associated modalities are used, such as the power 
Doppler imaging. In our study we evaluated the efficiency of power Doppler imaging in 
the detection of prostate cancer.
The mean age of the patients was 65.6 years ranging from 55 to 80 years, majority 
were in the age group between 56 and 70 years, around 80%. The age group of our 
population  was  comparable  to  those  in  the  literature,  involving  prostate  cancer.  On 
stratifying the patients according to the age group, patients in the age group between 56 
and 70 years  had  proportionately  higher  incidence  of  negative  biopsies  and the  age 
group  of  66  to  70  years  had  higher  incidence  of  positive  biopsies.  This  shows the 
increasing incidence of prostate cancer with age.
Only 10% of the patients had prostate size of more than 50ml. this shows that size 
of  the  prostate  does  not  signify  the  presence  or  absence  of  malignancy.  The  mean 
prostate size was 32.7 grams ranging from 12 to 155 ml. Prostate size did not correlate 
with the presence of ca prostate, correlation coefficient -0.06..
Serum PSA is the other important investigation done to diagnose prostate cancer. 
PSA ranged from 3 ng/ml to 756ng/ml. The mean PSA was 41.4 ng/ml. The mean serum 
PSA in  cancer  positive  patients  was  44.26ng/ml  and 18.2  ng/ml  in  cancer  negative 
patients. Though PSA more than 4 ng/ml is considered to be suggestive of ca prostate, 
the higher incidence of infections (prostatitis) in Indian patients may cause elevation of 
serum PSA. So a high PSA may not be suggestive of cancer until it is proved by biopsy. 
More than 70% of patients with PSA >20 ng/ml had carcinoma prostate.
56 out of 75 patients with carcinoma had positive DRE. This gives a sensitivity of 
76%. This is considered high comparing the literature values of between 40 to 70%. This 
might be due to the predominant presentation of patients with higher tumour stages in 
the Indian scenario.
Hypoechoic area directed biopsy was the modality of diagnosis practiced in the 
late 1980s51-52. The hypoechoic nodule directed biopsies were found to have a sensitivity 
of around 70% and specificity on the range of 60%. In our study, the sensitivity was 
62.7%, Specificity was 66.7%, Positive Predictive value 72.3% and Negative predictive 
value was 56%.. this shows the poor efficacy of hypoechoic nodule directed biopsy in 
the detection of prostate cancer.
Tumours are found to be hypervascular due to the neovascularity. Power Doppler 
imaging,  which  deciphers  the  tissue  vascularity,  may  be  used  in  the  evaluation  of 
vascularity of lesions. Biopsies directed towards the hypervascular areas were found to 
have a higher sensitivity of around 90% and specificity of 85% in various studies69-81. In 
our study, the sensitivity was 88.5% for detection of cancer in comparison with 10 core 
biopsy.  This  shows  that  hypervascular  area  directed  biopsy  definitely  scores  over 
hypoechoic area directed biopsy in the detection of prostate cancer.
Overall 58% patients were detected to have cancer. It is higher when compared to 
the literature, which varies from 36% to 55%. The higher percentage in our study could 
be due to the large number of patients with both elevated PSA and positive DRE. The 
Indian patients moreover present late compared with the west. The overall sensitivity of 
power Doppler in the detection of prostate cancer in our study was 88.5 % similar to the 
previous studies. The specificity of 79.8% was comparable with the world literature. The 
positive predictive value of 84.6% was similar to other studies. The negative predictive 
value of 82.3% was comparably less than the world literature which varies from 78 to 
94%.
Table-13: Comparison of studies with power doppler
Ca (%) No.(Pts) Sen Spe PPV NPV Study
36 136 82.8%, 78.8%, 87.9% 89.7%, Remzi73
40 108 90%, 90% 84%, 94% Satoru74
55 323 92.4% 72% 83% 80.6% Sauvain78
36 36 90%, 75% 82% 88% Sakarya80
42 28 74%, 96% 74% 78% Franco83
40 108 90% 90% 84% 94% Takahashi69
58 129 88.5% 79.8% 84.6% 82.3% *
* - present study
One important point to note in our study is that in 3 patients with carcinoma, the 
tumour was picked up by hypervascular area directed biopsy, but it was not diagnosed 
by 10 core biopsy. In all these patients the prostate volume was more than 50ml. Though 
the values are not statistically significant,  we can advise hypervascular area directed 
biopsy combined with standard 10 core biopsy in patients with large prostates.  This 
finding correlates with the study by Saturo et al where 3 patients with a negative sextant 
biopsy had a positive targeted biopsy.75.
The  presence  of  hypervascularity  in  hypoechoic  nodules  is  associated  with  a 
positive  predictive  value  of  98%.  So if  a  patient  has  a  hypoechoic  nodule  showing 
hypervascularity, this is most likely to have a focus of tumour.
On  evaluating  the  statistical  parameters  using  the  test  of  proportions,  the 
difference in sensitivity and NPV between PDI and grey scale imaging was statistically 
significant with p value of <0.01. Difference in specificity and PPV had a p value of < 
0.05.
The complication rate in our study was 10%. This is equal to those reported in 
literature. The most common complication was UTI, which was managed conservatively 
with antibiotics. These infections do occur even after antibiotic prophylaxis, so patients 
need to be counselled prior to procedure. 4 patients had minimal hematuria which was 
managed conservatively.
To conclude, transrectal ultrasound with power Doppler imaging guided biopsy is 
more  sensitive  and  specific  compared  to  grey  scale  imaging.  Extended  core  biopsy 
protocol  though,  still  remains  the  gold  standard.  We  would  like  to  recommend 
hypervascular area directed biopsies combined with standard extended core biopsies in 
large prostates to increase the yield.
CONCLUSION
Power Doppler imaging guided hypervascular area directed biopsy is efficient in the 
detection of prostate cancer in comparison with hypoechoic nodule directed biopsy.
SUGGESTIONS:
Power Doppler guided targeted biopsy of hypervascular area, may be combined with 
extended core biopsy to increase the yield of core biopsy.
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Figure-9: Penetration depth 
22mm with sample notch  18mm
Figure-7: 7.5 MHz broadband 
endoluminal probe with biopsy gun 
attachment
Figure-6: SSD2000 System (Aloka, Japan)
Figure-8:  Bard max core biopsy 
needle, 18 g x 25 cm length
Figure-11: Normal prostate gland
Figure-10: Biopsy core being taken
Figure-12: Hypoechoic area 
Figure-13: Hypervascular area 
MASTER CHART
No Age
LUTS 
(months) DRE PSA Pr Vol Hypo PDI Combined 10 core
1 75 6 Yes 8 22 Yes Yes Yes Yes
2 60 4 No 34 14 Yes No No No
3 70 6 Yes 54 34 Yes Yes No Yes
4 60 8 Yes 22 35 Yes Yes No Yes
5 75 6 Yes 765 45 Yes Yes Yes Yes
6 78 8 Yes 3 76 No No No Yes
7 78 5 No 23 80 No No No No
8 65 6 Yes 22 12 Yes Yes Yes Yes
9 53 7 No 11 23 Yes Yes No Yes
10 60 6 No 4 43 No No No No
11 80 5 Yes 34 154 Yes Yes No Yes
12 57 4 Yes 34 34 Yes Yes Yes Yes
13 75 12 Yes 13 25 No Yes No Yes
14 61 8 Yes 15 24 Yes No No Yes
15 64 11 Yes 25 32 No Yes No Yes
16 60 5 No 43 13 No No No No
17 58 9 No 66 23 No Yes No Yes
18 69 7 No 23 21 Yes Yes Yes Yes
19 75 12 Yes 7 21 Yes Yes Yes Yes
20 60 7 No 10 32 No No No No
21 66 6 No 18 12 Yes Yes Yes Yes
22 75 18 Yes 35 13 Yes Yes Yes Yes
23 58 8 Yes 18 43 Yes Yes Yes Yes
24 68 9 Yes 38 32 Yes Yes Yes Yes
25 77 12 Yes 15 23 Yes Yes Yes Yes
26 60 5 No 15 21 Yes No No No
27 72 8 Yes 16 32 Yes Yes No Yes
28 57 6 No 6 12 No No No No
29 78 18 Yes 26 24 No Yes No Yes
30 65 10 No 22 22 Yes Yes Yes Yes
31 65 4 Yes 23 23 No No No Yes
32 60 6 Yes 97 25 Yes Yes Yes Yes
33 74 11 No 104 26 Yes Yes Yes Yes
34 69 1 Yes 45 27 No Yes No Yes
35 60 6 No 64 24 Yes Yes No Yes
36 65 9 No 24 17 No No No No
37 65 10 No 35 18 No Yes No Yes
38 78 1 Yes 64 19 Yes Yes Yes Yes
39 70 18 No 28 14 No Yes No Yes
40 64 8 Yes 34 23 No Yes No Yes
41 63 5 Yes 29 26 Yes Yes Yes Yes
42 66 7 Yes 17 29 Yes Yes Yes Yes
43 60 6 Yes 22 155 Yes Yes Yes Yes
44 71 12 No 13 34 No No No Yes
45 59 3 No 14 32 No No No No
46 68 18 No 24 20 No Yes Yes Yes
47 63 6 Yes 45 27 Yes Yes Yes Yes
48 70 10 Yes 47 34 No Yes No Yes
49 58 4 Yes 68 56 Yes Yes Yes Yes
50 66 5 Yes 45 54 No Yes No Yes
51 57 6 Yes 62 34 No No No No
52 68 8 Yes 44 23 No Yes No Yes
53 67 18 No 35 38 Yes Yes No Yes
54 78 9 No 25 28 No No No Yes
55 69 8 No 34 26 Yes Yes Yes Yes
56 65 6 Yes 26 19 No Yes No Yes
57 58 4 Yes 22 20 No Yes No Yes
58 68 9 No 13 53 No No No No
59 64 11 Yes 24 44 Yes Yes Yes Yes
60 63 8 Yes 24 45 Yes Yes Yes Yes
61 60 6 Yes 12 24 No Yes No Yes
62 58 5 Yes 14 25 Yes No No Yes
63 70 18 Yes 15 27 No Yes No Yes
64 68 4 No 34 26 Yes No No No
65 59 6 Yes 23 28 Yes Yes Yes Yes
66 67 10 Yes 22 29 No Yes No Yes
67 65 9 Yes 12 44 No No No No
68 65 7 Yes 13 34 Yes Yes No Yes
69 62 8 Yes 23 18 No Yes No Yes
70 65 1 Yes 13 18 Yes No No No
71 60 3 Yes 15 27 No Yes No Yes
72 60 8 Yes 212 29 No No No No
73 76 10 Yes 632 36 Yes Yes Yes Yes
74 69 7 No 23 37 Yes Yes No Yes
75 69 8 No 11 29 No No No Yes
76 66 9 No 13 29 Yes Yes Yes Yes
77 60 5 Yes 14 19 No Yes No Yes
78 65 1 Yes 18 34 No No No Yes
79 73 1 Yes 57 60 Yes Yes Yes Yes
80 69 10 Yes 55 45 No No No No
81 75 14 Yes 26 27 Yes Yes No Yes
82 60 6 Yes 11 27 Yes Yes Yes Yes
83 61 5 Yes 10 25 No No No No
84 68 4 No 8 22 Yes No No No
85 63 7 Yes 63 34 No Yes No Yes
86 69 3 Yes 14 58 Yes Yes Yes Yes
87 64 7 Yes 26 23 Yes No No No
88 78 15 No 32 36 Yes Yes No Yes
89 64 5 Yes 40 62 Yes Yes Yes Yes
90 65 11 Yes 16 45 Yes Yes No No
91 66 16 Yes 45 18 No No No No
92 63 8 No 63 44 No Yes No Yes
93 74 2 Yes 18 48 Yes Yes Yes Yes
94 62 8 No 28 15 Yes No No No
95 73 5 Yes 36 50 Yes No No Yes
96 61 17 Yes 6 18 No Yes No No
97 66 12 No 50 44 No No No No
98 77 6 Yes 76 25 Yes Yes Yes Yes
99 64 6 Yes 44 24 Yes Yes Yes Yes
100 61 10 Yes 20 46 Yes No No No
101 66 8 Yes 18 22 No Yes No No
102 65 5 No 42 45 No Yes No No
PROFORMA
S.No:
Name: Address:
Age:
History:
Hesitancy Intermittency Incomplete emptying
Nocturia Frequency Dysuria
Straining Thin stream
Red / White urine
Others 
Past History:
DM / HT/ TB/ BA/ CAD/ Previuos Surgeries
Personal history:
Smoking / Alcohol intake
Family History:
EXAMINATION:
Pallor/ Icterus/ Cyanosis/ Clubbing/ Edema/ Lymphadenopathy
PR: BP:
CVS:
RS:
P/A:
CNS: Spine / cranium
EG:
DRE: Prostate – Grade
Nodule
Tone
INVESTIGATIONS:
Urine: Albumin: Blood: Sugar:
Sugar: Urea:
Deposits: Creatinine
C/S: Hb:
ESR:
TC/DC:
Serum PSA
:
USG KUB: Kidney Right Left. 
PCS PCS
CMD CMD
Bladder:
Prostate: Volume
PVR:
TRUS: Prostate Volume
Hypoechoic area
Hypervascularity
Combined
Biopsy: (+/-)Hypoechoic area         
Hypervascularity
Combined
